Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PBYI · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) NCT07465757 · Small Cell Lung Cancer ( SCLC ) Alisertib, Alisertib | PBYI Puma Biotechnology, Inc. | Phase 2 | Recruiting | 50 | Mar 31, 2028 | Registry ↗ |
| Oct 1, 2026 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negat… NCT06369285 · Hormone Receptor Positive HER-2 Negative Breast Cancer, Met… Alisertib, Endocrine therapy | PBYI Puma Biotechnology, Inc. | Phase 2 | Recruiting | 225 | Dec 30, 2027 | Registry ↗ |
| Aug 17, 2026 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer NCT06095505 · Small Cell Lung Cancer Alisertib | PBYI Puma Biotechnology, Inc. | Phase 2 | Recruiting | 120 | Oct 30, 2027 | Registry ↗ |
| Mar 12, 2024 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18… NCT01953926 · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutatio… Neratinib, Fulvestrant | PBYI Puma Biotechnology, Inc. | Phase 2 | Terminated | 582 | Jan 2, 2023 | Registry ↗ |
| Feb 10, 2023 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With… NCT04366713 · HER2 Amplified Breast Cancer Neratinib, Capecitabine | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 6 | Dec 28, 2021 | Registry ↗ |
| May 6, 2022 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-S… NCT02400476 · Early Stage HER2+ Breast Cancer Neratinib, Loperamide | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 563 | Apr 22, 2021 | Registry ↗ |
| Jun 11, 2021 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Me… NCT01808573 · HER2+ Metastatic Breast Cancer (MBC) neratinib, capecitabine | PBYI Puma Biotechnology, Inc. | Phase 3 | Completed | 621 | Sep 28, 2018 | Registry ↗ |
| Jun 11, 2021 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Brea… NCT00878709 · Breast Cancer neratinib, placebo | PBYI Puma Biotechnology, Inc. | Phase 3 | Completed | 2,840 | Aug 21, 2014 | Registry ↗ |
| May 19, 2021 | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into… NCT03786107 · Hormone Receptor-Positive, HER2-Negative Metastatic Breast… Almac HER-Seq Assay | PBYI Puma Biotechnology, Inc. | — | Terminated | 1,583 | Jan 21, 2021 | Registry ↗ |
| Dec 19, 2018 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor NCT01128842 · Advanced Malignant Solid Tumors Neratinib, Capecitabine | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 7 | Mar 2011 | Registry ↗ |
| Nov 19, 2018 | Study Evaluating Safety And Tolerability, Solid Tumor NCT00768469 · Advanced Malignant Solid Tumors Neratinib, Paclitaxel | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 10 | Jan 2011 | Registry ↗ |
| Sep 26, 2018 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast C… NCT01111825 · Breast Cancer Temsirolimus, Neratinib | PBYI Puma Biotechnology, Inc. | Phase 1/2 | Completed | 99 | Jul 2016 | Registry ↗ |
| Sep 18, 2018 | Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors NCT00838539 · Neoplasms, Malignant Carcinoma Neratinib, Temsirolimus | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 63 | Jun 2011 | Registry ↗ |
| Sep 17, 2018 | Study Evaluating HKI-272 in Tumors NCT00146172 · Breast Neoplasms neratinib | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 73 | Jan 2007 | Registry ↗ |
| Sep 14, 2018 | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Adv… NCT00397046 · Tumors neratinib | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 21 | Mar 2009 | Registry ↗ |
| Sep 5, 2018 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer NCT00741260 · Breast Cancer Neratinib, Capecitabine | PBYI Puma Biotechnology, Inc. | Phase 1/2 | Completed | 105 | Nov 2010 | Registry ↗ |
| Aug 22, 2018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanc… NCT00915018 · Breast Cancer Neratinib, Trastuzumab | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 479 | Aug 2013 | Registry ↗ |
| Aug 14, 2018 | Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer NCT00300781 · Breast Neoplasms, Neoplasms neratinib | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 136 | Apr 2008 | Registry ↗ |
| Aug 9, 2018 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Ca… NCT00777101 · Advanced Breast Cancer, Breast Cancer Neratinib, Lapatinib | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 233 | Mar 2011 | Registry ↗ |
| Aug 9, 2018 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors… NCT00706030 · Breast Cancer, Advanced Malignant Solid Tumors neratinib, vinorelbine | PBYI Puma Biotechnology, Inc. | Phase 1/2 | Completed | 92 | Oct 2009 | Registry ↗ |
| Jul 26, 2018 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With So… NCT00445458 · Advanced Breast Cancer, Advanced Malignant Solid Tumors HKI-272, Paclitaxel | PBYI Puma Biotechnology, Inc. | Phase 1/2 | Completed | 110 | May 2011 | Registry ↗ |
| Jul 24, 2018 | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects Wi… NCT00398567 · Advanced Breast Cancer HKI-272, trastuzumab | PBYI Puma Biotechnology, Inc. | Phase 1/2 | Completed | 45 | Jul 31, 2009 | Registry ↗ |
| Jul 3, 2018 | Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Ce… NCT01827267 · HER2-mutant Non-Small Cell Lung Cancer neratinib, temsirolimus | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 62 | Sep 20, 2016 | Registry ↗ |
| Jun 28, 2018 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic… NCT00958724 · Advanced Malignant Solid Tumors Neratinib, Vinorelbine | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 6 | Apr 2010 | Registry ↗ |
| Apr 13, 2018 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Ca… NCT00266877 · Carcinoma, Non-Small-Cell Lung, Lung Neoplasms HKI-272 | PBYI Puma Biotechnology, Inc. | Phase 2 | Completed | 172 | Jan 2009 | Registry ↗ |
| Sep 11, 2017 | Study Evaluating HKI-272 Administered to Healthy Subjects NCT00366600 · Healthy neratinib | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 56 | Dec 2006 | Registry ↗ |
| May 11, 2016 | Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects NCT02334501 · Healthy Lansoprazole, Neratinib | PBYI Puma Biotechnology, Inc. | Phase 1 | Completed | 15 | Oct 2014 | Registry ↗ |
27 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances